

ASX Announcement

Latest Azer-cel Data Selected for Oral Presentation at 2026 ASCO Annual Meeting

Sydney, Australia, 1 April 2026: Imugene Limited (ASX: IMU), a clinical-stage immunology company is pleased to announce that data from its lead program, **azer-cel**, has been selected for oral presentation at the **2026 American Society of Clinical Oncology (ASCO) Annual Meeting**.

Held on 29 May – 2 June, in Chicago, **ASCO** is the world's leading oncology conference, bringing together more than 40,000 oncology professionals, researchers, and investors globally. This year, more than 8,500 abstracts were reviewed by the Scientific Program Committee – selection for oral presentation represents a significant recognition of the clinical merit of the data.

Further details of the presentation, including session information and timing, will be announced April 21, 2026, in accordance with ASCO's abstract release policies.

The full abstract will be published on the ASCO website on 21 May 2026 at asco.org/abstracts. Following the conference, the presentation will be available on Imugene's website at <https://imugene.com/investors/conference-presentations/>

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

General Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
communications@imugene.com



Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (onCARlytics) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies may become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.